International Biotechnology (IBT)
Latest Research
International Biotechnology (IBT) is the top-performing biotech trust over the past five years. Managers Ailsa Craig and Marek Poszepczynski have successfully implemented a strategy that mixes top-down positioning with bottom-up analysis to navigate a difficult period for biotech and then a sharp recovery rally, outperforming in both rising and falling markets (see Performance).
In recent months, the managers have dialled back their positioning in small caps and their gearing, conscious of the market’s vulnerability after such a strong run, a slowdown in M&A activity and the prospect of rate hikes in the US. However, they remain bullish on the outlook for the industry due to some powerful industry fundamentals. Large cap pharma is still facing a looming patent cliff which means there is a strong imperative to acquire biotech companies with new drugs. Meanwhile, advances are being made on a number of modalities, meaning there is the prospect of many effective and lucrative new treatments in the coming years. Ailsa and Marek have positioned the portfolio where they think the medical need is high and the competing products are low, and increased the portfolio’s weighting to the more mature and clinically de-risked companies.
IBT pays a dividend equal to 4% of the previous year’s closing NAV. With such a strong 12 months to 31/08/2026, the dividend should rise by c. 50% for FY 2027. With the payout split into two 6-monthly instalments, this increase is not incorporated into the historical yield figures being quoted.
The trust’s Discount remained relatively narrow, at 4.7% at the time of writing, despite a slight decline in the NAV and share price since July.
Kepler Trust Intelligence provides research and information for professional and private investors. In order to ensure that we provide you with the right kind of content, and to ensure that the content we provide is compliant, you need to tell us what type of investor you are.
ContinueUpcoming Events
Replay
Rewatch our series of webinars throughout March and hear from some of the top fund managers talking about the investment outlook for a wide range of asset classes and geographies.

































